+ Watch CFN
on My Watchlist
The company offers clinical and medical products for infusion, surgical procedures, medical diagnostics, medication and supply dispensing, infection prevention, and respiratory care.
Recent spinoff of CAH. CAH retains 20% of stock and must sell within 5 years- only one reason for them to retain- they think it is offers a very attractive rate of return over that time period. Insider buys and significant insider incentive through RSUs / stock plan for employees. CFN of course also stands to benefit from a very nice pop once the healthcare debate is wrapped up in Washington, and substantively CFN probably has a number of offers which actually can/will reduce the cost of healthcare in this country over the long term.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions